摘要:
The invention relates to compounds of a general formula (I): wherein Ar1 is an optionally-substituted aryl or heteroaromatic group; R1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R3 is a hydrogen atom or a lower alkyl group; R4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R1k)R1m; T and U are a nitrogen atom or a methine group, etc.The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.
摘要翻译:本发明涉及通式(I)的化合物:其中Ar 1是任选取代的芳基或杂芳基; R 1是任选取代的低级烷基,低级烯基,低级炔基或环 - 低级烷基,或者是任选具有取代基的芳基,芳烷基或杂芳族基团; R 2是氢原子,低级烷基,低级烯基或低级炔基,或者是任选具有取代基的芳基,芳烷基或杂芳基; R 3是氢原子或低级烷基; R 4是氢原子,卤素原子,羟基,低级烷基或-N(R 1)1个基团)的基团, SUP>; T和U是氮原子或次甲基等。本发明的化合物具有优异的韦尔激酶抑制作用,因此可用于药物领域,特别是治疗各种癌症。
摘要:
The invention relates to compounds of a general formula (I): wherein Ar1 is an optionally-substituted aryl or heteroaromatic group; R1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R3 is a hydrogen atom or a lower alkyl group; R4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R1k)R1m; T and U are a nitrogen atom or a methine group, etc. The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.
摘要翻译:本发明涉及通式(I)的化合物:其中Ar1是任选取代的芳基或杂芳基; R 1是任选取代的低级烷基,低级烯基,低级炔基或环低级烷基,或者是任选具有取代基的芳基,芳烷基或杂芳基; R2是氢原子,低级烷基,低级烯基或低级炔基,或者是任选具有取代基的芳基,芳烷基或杂芳基; R3是氢原子或低级烷基; R4是氢原子,卤素原子,羟基,低级烷基或-N(R1k)R1m基团; T和U是氮原子或次甲基等。本发明的化合物具有优异的韦尔激酶抑制作用,因此可用于药物领域,特别是治疗各种癌症。
摘要:
The present invention relates to a compound represented by Formula [I]: wherein X is O, S, NH or CH2; Y1, Y2, Y3, Y4 and Y5, which may be identical or different, are each CH or N; however, at least one of Y1, Y2, Y3, Y4 and Y5 is N; Z1 and Z2, which may be identical or different, are each CH or N; n is an integer from 1 to 3; R1 is a C3-C8 cycloalkyl group, a C6-C10 aryl group, an aliphatic heterocyclic ring or an aromatic heterocyclic ring, or a bicyclic aliphatic saturated hydrocarbon group; R2 and R3, which may be identical or different, are each a hydrogen atom, a lower alkyl group, a lower alkenyl group, a C3-C8 cycloalkyl group, a C6-C10 aryl group, an aromatic heterocyclic ring, or the like; and R4 is a hydrogen atom, a lower alkyl group, a C3-C6 cycloalkyl group or the like, or a pharmaceutically acceptable salt or ester thereof, and a selective inhibitor against Cdk4 and/or Cdk6 or an anticancer agent containing the compound or a pharmaceutically acceptable salt or ester thereof.
摘要翻译:本发明涉及由式[I]表示的化合物:其中X是O,S,NH或CH 2; Y 1,Y 2,Y 3,Y 4和Y 5, 其可以相同或不同,各自为CH或N; 然而,Y 1,Y 2,Y 3,Y 4和Y 3中的至少一个, 5 SUB>是N; Z 1和Z 2可以相同或不同,各自为CH或N; n为1〜3的整数, R 1是C 3 -C 8环烷基,C 6 -C 10环烷基,C 6 -C 15环烷基, 芳基,脂族杂环或芳族杂环,或双环脂族饱和烃基; R 2和R 3可以相同或不同,分别为氢原子,低级烷基,低级烯基,C 3, C 1 -C 8环烷基,C 6 -C 10芳基,芳族杂环等; 和R 4是氢原子,低级烷基,C 3 -C 6环烷基等,或药学上可接受的 盐或酯,以及对Cdk4和/或Cdk6的选择性抑制剂或含有该化合物或其药学上可接受的盐或酯的抗癌剂。
摘要:
A porous composite material for diaphragms for high-output electrochemical cells such as lithium cells. The material is a layered structure of fluoropolymer and polyolefin that provides a shut-down capability that safeguards against dangerous failure of the cell, such as a rupture or fire that may result from a short-circuit or other high-rate electric discharge.
摘要:
The present invention relates to a compound of formula I: wherein: R1 is C1-6 alkyl, C3-8 cycloalkyl, aryl, heterocyclyl, or —COR1x, where the C1-6 alkyl, C3-8 cycloalkyl, aryl, and heterocyclyl may be substituted; and R1x is C3-8 cycloalkyl, aryl, or heterocyclyl, any of which may be substituted; R2, R3, R4, R5, R6, and R7 are each independently hydrogen, halogen, C1-6 alkyl, or aryl, where the C1-6 alkyl or aryl may be substituted; R8 is hydrogen, C1-6 alkyl, aryl, or heterocyclyl, any of which may be substituted; or a pharmaceutically acceptable salt or ester thereof.
摘要:
An input signal is input via a first resistor to an inverting input terminal of an operational amplifier. A second resistor is provided on a feedback path between an output terminal and the inverting input terminal of the operational amplifier. A control voltage Vcnt output from the operational amplifier is input to a VCO. A frequency divider frequency-divides an output signal Sout of the VCO. A phase comparator compares an output signal from the frequency divider with a reference clock signal and outputs a voltage according to a phase difference. A loop filter removes a high-frequency component of an output voltage Vcp of the phase comparator and outputs the voltage to a non-inverting input terminal of the operational amplifier.
摘要:
The invention relates to compounds of a general formula (I): wherein Ar1 is an optionally-substituted aryl or heteroaromatic group; R1 is an optionally-substituted lower alkyl, lower alkenyl, lower alkynyl or cyclo-lower alkyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R2 is a hydrogen atom, a lower alkyl group, a lower alkenyl group or a lower alkynyl group, or is an aryl, aralkyl or heteroaromatic group optionally having a substituent; R3 is a hydrogen atom or a lower alkyl group; R4 is a hydrogen atom, a halogen atom, a hydroxyl group, a lower alkyl group or a group of —N(R1k)R1m; T and U are a nitrogen atom or a methine group, etc.The compounds of the invention have excellent Weel kinase-inhibitory effect and are therefore useful in the field of medicines, especially treatment of various cancers.
摘要翻译:本发明涉及通式(I)的化合物:其中Ar1是任选取代的芳基或杂芳基; R 1是任选取代的低级烷基,低级烯基,低级炔基或环低级烷基,或者是任选具有取代基的芳基,芳烷基或杂芳基; R2是氢原子,低级烷基,低级烯基或低级炔基,或者是任选具有取代基的芳基,芳烷基或杂芳基; R3是氢原子或低级烷基; R4是氢原子,卤素原子,羟基,低级烷基或-N(R1k)R1m基团; T和U是氮原子或次甲基等。本发明的化合物具有优异的韦尔激酶抑制作用,因此可用于药物领域,特别是治疗各种癌症。
摘要:
The invention provides the compounds represented by the formula (I) in which, R stands for a dihydroxy-substituted C1-C6 alkyl group, and Cy stands for an optionally substituted C6-C10 bi- or tri-cyclic aliphatic carbocyclic group. These compounds act as nociceptin receptor antagonist, and are useful, for example, as relievers against tolerance to narcotic analgesic, dependence on narcotic analgesic or addiction; analgesic enhancers; antiobestic or appetite suppressors; treating or prophylactic agents for cognitive impairment and dementia/amnesia; agents for treating developmental cognitive abnormality; remedy for schizophrenia; agents for treating neurodegenerative diseases; anti-depressant or treating agents for affective disorder; treating or prophylactic agents for diabetes insipidus; treating or prophylactic agents for polyuria; and remedy for hypotension and the like.
摘要:
The invention provides the compounds represented by the formula (I) in which, R stands for a dihydroxy-substituted C1-C6 alkyl group, and Cy stands for an optionally substituted C6-C10 bi- or tri-cyclic aliphatic carbocyclic group. These compounds act as nociceptin receptor antagonist, and are useful, for example, as relievers against tolerance to narcotic analgesic, dependence on narcotic analgesic or addiction; analgesic enhancers; antiobestic or appetite suppressors; treating or prophylactic agents for cognitive impairment and dementia/amnesia; agents for treating developmental cognitive abnormality; remedy for schizophrenia; agents for treating neurodegenerative diseases; anti-depressant or treating agents for affective disorder; treating or prophylactic agents for diabetes insipidus; treating or prophylactic agents for polyuria; and remedy for hypotension and the like.
摘要:
The FM transmitter converts an input audio signal to a stereo composite signal, frequency-modulates the stereo composite signal and outputs the obtained signal. A stereo modulator stereo-modulates the output signal of the filter circuit, and converts the signal to the stereo composite signal. A frequency modulator frequency-modulates based on the stereo composite signal output from the stereo modulator. The filter circuit includes a pre-emphasis circuit, a low pass filter and the like, for example. At least one part of the filter circuit, that is, the low pass filter or the pre-emphasis circuit is configured with a switched capacitor filter.